CST
ONC

Charles Schwab Trust’s BeOne Medicines Ltd ONC Stock Holding History

Charles Schwab Trust’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$855K Buy
+3,000
New +$884K 0.05% 106

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab Trust's ONC Position: Q2 2026 in Review

Charles Schwab Trust opened a new position in BeOne Medicines Ltd (ONC) in Q2 2026: 3,000 shares worth $855K. The stake represents 0.05% of the portfolio and ranks #106 among its holdings.

282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Charles Schwab Trust held 3,000 shares of BeOne Medicines Ltd worth $855K as of Q2 2026.
  • BeOne Medicines Ltd was a new Charles Schwab Trust position in Q2 2026.
  • BeOne Medicines Ltd made up 0.05% of Charles Schwab Trust's portfolio in Q2 2026, its #106 holding.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Charles Schwab Trust's 13F filing for Q2 2026, filed 10 Jul 2026.